

## COUNTRY GENERAL INFORMATION

Total population:	40 222 503
Gender F/M (%):	49.4 / 50.6
Population, age group <15 / ≥ 15 years (%):	38 / 62
Life expectancy at birth (F/M, years):	75 / 70
GDP (PPP int \$):	11 363
Income status:	Upper middle income
Number of 2 <sup>nd</sup> sub-national administrative level divisions, name:	148, District



## EPIDEMIOLOGY

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	61	8 691	N/A	N/A
Number of relapses: <sup>1</sup>	No data	No data	N/A	N/A
<b>Total number of cases:</b>	<b>61</b>	<b>8 691</b>	<b>N/A</b>	<b>N/A</b>
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	44	44	N/A	N/A
Age group distribution (% , <5 / 5-14 / >14):	95 / 3 / 2	28 / 30 / 41	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	No data	No data	N/A	N/A
Number of endemic 2 <sup>nd</sup> sub-national administrative level divisions:	65	114	N/A	N/A
Population at risk (% , # at risk / total population): <sup>2</sup>	No data	No data	N/A	N/A
Was there any outbreak?	No data	No data	N/A	N/A
Number of new foci: <sup>3</sup>	No data	No data	N/A	N/A



## Monthly distribution of new cases (January-December)

2020	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	12	7	17	5	4	0	0	1	0	1	5	5
CL	1 750	898	348	177	95	79	109	186	356	628	1 313	2 339

N/A not applicable; VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis



## Number of new cases and Incidence rate/10 000 at the national level from 2005 to 2020



<sup>1</sup>Relapse in this country is defined for CL as "incomplete epithelialization of skin lesion" and for VL as "recurrence of VL symptoms with parasitological confirmation" at any time point after initial cure"

<sup>2</sup>Defined as "Number of people living in 2<sup>nd</sup> sub-national administrative level endemic areas"

<sup>3</sup>Defined as "No definition available"

## Disease distribution of new cases at District level per 10 000 population (2020)

No district population data for 2020

### CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1997
Type of surveillance (CL / VL):	Vertical / Vertical
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin WG
Year latest national guidelines (CL / VL):	No data / No data
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities (CL / VL):	151 / 99

### DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	No data	No data	N/A	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	No data	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

### TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Sodium stibogluconate (SSG)

### INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	CL
Cases that completed treatment (% , # completed treatment / new cases):	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	No data	No data
Failure rate (% , # cases with treatment failure / new cases): <sup>4</sup>	No data	No data
Case fatality rate (% , # cases who died / new cases):	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

<sup>4</sup>Failure in this country is defined for CL as "persistence of recurrence during treatment or up to initial treatment outcome assessment" and for VL as "persistence of signs and symptoms or recurrence during treatment or up to initial treatment outcome assessment"